Phase I study of the second-generation, recombinant, human EGFR antibody necitumumab in Japanese patients with advanced solid tumors. (Q51507476)

6 April 2018

title

Phase I study of the second-generation, recombinant, human EGFR antibody necitumumab in Japanese patients with advanced solid tumors. (English)

1 reference

6 April 2018

Hajime Asahina

5

0 references

author name string

Yosuke Tamura

1

1 reference

6 April 2018

Hiroshi Nokihara

2

1 reference

6 April 2018

Kazunori Honda

3

1 reference

6 April 2018

Yuko Tanabe

4

1 reference

6 April 2018

Yasuhide Yamada

6

1 reference

6 April 2018

Sotaro Enatsu

7

1 reference

6 April 2018

Raffael Kurek

8

1 reference

6 April 2018

Noboru Yamamoto

9

1 reference

6 April 2018

Tomohide Tamura

10

1 reference

6 April 2018

publication date

15 September 2016

1 reference

6 April 2018

Cancer Chemotherapy and Pharmacology

published in

1 reference

6 April 2018

volume

78

1 reference

6 April 2018

page(s)

995-1002

1 reference

6 April 2018

issue

5

1 reference

6 April 2018

https://scigraph.springernature.com/pub.10.1007/s00280-016-3154-z

exact match

0 references

cites work

Mechanisms for oncogenic activation of the epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3154-Z

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3154-Z

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3154-Z

Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3154-Z

Platinum-based chemotherapy plus cetuximab in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3154-Z

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3154-Z

Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3154-Z

Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3154-Z

A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3154-Z

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3154-Z

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3154-Z

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3154-Z

Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3154-Z

A phase I escalating single-dose and weekly fixed-dose study of cetuximab pharmacokinetics in Japanese patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3154-Z

10.1007/S00280-016-3154-Z

21 January 2018

Identifiers

DOI

1 reference

6 April 2018

PubMed ID

27628194

1 reference

6 April 2018